Observational studyJournal of vascular surgery2021
Meaningful change in 6-minute walk in people with peripheral artery disease.
Observational study in Journal of vascular surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Home-Based Walking Exercise and Supervised Treadmill Exercise in Patients With Peripheral Artery Disease: An Individual Participant Data Meta-Analysis.JAMA network open · 2023Pooled it
- Acute lower leg transcutaneous electrical nerve stimulation increases leg blood flow and exercise capacity in patients with peripheral arterial disease.Experimental physiology · 2026Trial
- Remote Self-Report Assessment of Walking Impairment in Peripheral Artery Disease.Journal of the American Heart Association · 2026Trial
- Duration of Supervised Exercise Necessary for Meaningful Improvement in Peripheral Artery Disease.Journal of the American Heart Association · 2025Trial
- Home-Based Exercise and Patient-Reported Outcome Measures in Peripheral Artery Disease: The LITE Randomized Clinical Trial.The American journal of cardiology · 2025Trial
- Hepatocyte growth factor for walking performance in peripheral artery disease.Journal of vascular surgery · 2025Trial
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial.Nature communications · 2024Trial
- Trial
- Effects of home-based leg heat therapy on walking performance in patients with symptomatic peripheral artery disease: a pilot randomized trial.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Trial
- Trial
- Supervised Exercise Therapy Using Mobile Health Technology in Patients With Peripheral Arterial Disease: Pilot Randomized Controlled Trial.JMIR mHealth and uHealth · 2021Trial
- Trial
- The SickleFit Tele-Exercise Program for older adults with sickle cell disease: feasibility, acceptability, safety study.Blood red cells & iron · 2026Article
- Digital therapeutics in peripheral artery disease: a step forward, not yet across the finish line.European heart journal. Digital health · 2026Article
- A digital health program enhances walking capacity and health status in symptomatic peripheral artery disease.European heart journal. Digital health · 2026Article
- A Sedentary Behaviour Reduction Programme in Patients With Peripheral Arterial Disease: A Mixed-Method Feasibility Study.International journal of vascular medicine · 2026Article
- Minimal clinically important difference of the 6-Minute walk test and daily step count at 3 months following surgery for lumbar spinal stenosis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
- Development and feasibility testing of a new device for home-based leg heat therapy in patients with lower extremity peripheral artery disease.Journal of vascular surgery cases and innovative techniques · 2025Article
- The desat-max in 2-chair test appears to be a worthwhile parameter to identify sickness: An appraisal.The Indian journal of medical research · 2025Article
- Telmisartan modulates exercise responses in peripheral artery disease: Analyses of skeletal muscle from the TELEX Trial.JVS-vascular science · 2025Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
objectiveThe 6-minute walk test is a common outcome measure in clinical trials of people with lower extremity peripheral artery disease (PAD). However, what constitutes a meaningful change in the 6-minute walk distance has not been well defined for people with PAD. The present study related the change in the 6-minute walk distance to the degree of participant-reported improvement or decline in the 6-minute walk distance to define a meaningful change in the 6-minute walk distance for those with PAD.
methodsParticipants with PAD from three observational longitudinal studies completed the walking impairment questionnaire (WIQ) distance score and 6-minute walk at baseline and 1 year later. The WIQ distance score measures participants' perceived difficulty walking seven different distances without stopping (ranging from walking around the home to walking 5 blocks) on a 0 to 4 Likert scale, with 0 representing an inability to walk the distance and 4 representing no difficulty. The mean changes in the 6-minute walk distance corresponding to the participants' report of no change, 1-unit change, or 2-unit change, respectively, in the Likert scale score between the baseline and 1-year follow-up measures were calculated for each WIQ distance.
resultsA total of 777 participants with PAD (mean age, 71.2 ± 8.8 years; mean baseline 6-minute walk distance, 350.1 ± 118.1 meters) completed 5439 questions about their difficulty walking each WIQ distance at baseline and follow-up. Participants with PAD who reported no change in their difficulty in walking each WIQ distance between baseline and follow-up had a decline of 7.2 meters (95% confidence interval [CI], -11.6 to -2.8 meters) in the 6-minute walk test. Relative to those reporting no change in difficulty walking, the participants reporting 1- and 2-point improvements in walking ability showed 6-minute walk distance improvements of 7.8 meters (95% CI, -0.3 to 15.9 meters) and 20.1 meters (95% CI, 1.1-39.2 meters), respectively. Relative to those reporting no change in walking difficulty, those reporting 1- and 2-point declines in perceived walking difficulty showed declines of -11.2 meters (95% CI, -19.0 to -3.4 meters) and -23.8 meters (95% CI, -37.4 to -10.3 meters) in the 6-minute walk distance.
conclusionsAmong people with PAD, ∼8- and ∼20-meter improvements in the 6-minute walk distance represent small and large improvements in walking ability, respectively. People with PAD who reported no change in their ability to walk distances over 1 year simultaneously declined by a mean of 7 meters in the 6-minute walk test. These findings will be useful for interpreting the results from randomized trials of interventions to improve the walking performance of people with PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.